

John W. Eikelboom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9156826/publications.pdf>

Version: 2024-02-01

717
papers

80,612
citations

906

116
h-index

471

271
g-index

738
all docs

738
docs citations

738
times ranked

45092
citing authors

#	ARTICLE	IF	CITATIONS
1	Conduit selection and early graft failure in coronary artery bypass surgery: A post hoc analysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) coronary artery bypass grafting study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 1080-1089.e1.	0.8	12
2	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	3.8	8
3	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. <i>Cardiovascular Research</i> , 2022, 118, 897-903.	3.8	17
4	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	3.0	8
5	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 648-659.	3.0	11
6	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	3.8	18
7	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	1.8	18
8	Aortic plaque burden predicts vascular events in patients with cardiovascular disease: The EAST-NOGA study. <i>Journal of Cardiology</i> , 2022, 79, 144-152.	1.9	12
9	Prolonged Blood Storage and Risk of Posttransfusion Acute Kidney Injury. <i>Anesthesiology</i> , 2022, 136, 138-147.	2.5	1
10	Advances in anticoagulation: patients with bioprosthetic heart valves. <i>Cardiovascular Research</i> , 2022, 118, e26-e28.	3.8	2
11	Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812110692.	1.1	0
12	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
13	Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. <i>Trials</i> , 2022, 23, 101.	1.6	10
14	Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110739.	1.7	0
15	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. <i>Thrombosis and Haemostasis</i> , 2022, 122, 998-1005.	3.4	19
16	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study. <i>TH Open</i> , 2022, 06, e10-e17.	1.4	4
17	Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease. <i>Canadian Journal of Cardiology</i> , 2022, 38, 588-600.	1.7	7
18	Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. <i>European Stroke Journal</i> , 2022, 7, 92-98.	5.5	8

#	ARTICLE	IF	CITATIONS
19	Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12650.	2.3	7
20	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. <i>Circulation</i> , 2022, 145, 626-628.	1.6	9
21	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. <i>CJC Open</i> , 2022, 4, 568-576.	1.5	4
22	Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and knee Replacement (PEPPER): the PEPPER trial protocol. <i>BMJ Open</i> , 2022, 12, e060000.	1.9	11
23	Tranexamic Acid in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2022, 386, 1986-1997.	27.0	125
24	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	3.0	6
25	Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS ₂ -P2A2RC score. <i>European Heart Journal</i> , 2022, 43, 996-1004.	2.2	8
26	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15
27	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. <i>Circulation</i> , 2022, 145, 1875-1877.	1.6	1
28	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. <i>European Heart Journal</i> , 2022, 43, 3542-3552.	2.2	7
29	Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 302-306.	3.5	11
30	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2021, 6, 21-29.	6.1	33
31	Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. <i>Cardiovascular Research</i> , 2021, 117, 2030-2044.	3.8	27
32	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021, 117, 576-584.	3.8	31
33	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.	3.8	15
34	Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?. <i>Future Cardiology</i> , 2021, 17, 175-182.	1.2	1
35	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021, 126, 163-171.	3.4	29
36	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 172-180.	3.4	8

#	ARTICLE	IF	CITATIONS
37	Direct Oral Anticoagulant Dosing in Extremes of Body Weight: Time to Revisit the Guidelines?. Thrombosis and Haemostasis, 2021, 121, 118-120.	3.4	8
38	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. Thrombosis and Haemostasis, 2021, 121, 518-528.	3.4	8
39	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	2.8	11
40	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. American Heart Journal, 2021, 233, 48-58.	2.7	11
41	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. TH Open, 2021, 05, e84-e88.	1.4	2
42	Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery. , 2021, , 71-91.		0
43	The Indirect Consequences of the Response to the COVID-19 Pandemic. Journal of the American College of Cardiology, 2021, 77, 186-188.	2.8	3
44	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
45	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. Thrombosis and Haemostasis, 2021, 121, 1097-1106.	3.4	14
46	Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e71-e71.	3.0	1
47	Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. Med, 2021, 2, 233-242.	4.4	1
48	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. European Heart Journal, 2021, 42, 2765-2775.	2.2	119
49	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. Journal of the American College of Cardiology, 2021, 77, 1903-1921.	2.8	150
50	Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. Circulation, 2021, 143, 1863-1873.	1.6	28
51	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart, 2021, 107, 1130-1137.	2.9	6
52	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. European Cardiology Review, 2021, 16, e26.	2.2	7
53	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke, 2021, 52, 2096-2105.	2.0	25
54	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). American Journal of Cardiology, 2021, 149, 27-35.	1.6	11

#	ARTICLE	IF	CITATIONS
55	Reply. Journal of the American College of Cardiology, 2021, 77, 2757.	2.8	0
56	What is the role of growth-differentiation factor-15 in biomarker-based prediction of mortality in patients with atrial fibrillation?. European Journal of Internal Medicine, 2021, 88, 23-24.	2.2	2
57	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	2.8	31
58	Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease. PLoS ONE, 2021, 16, e0253792.	2.5	1
59	Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. European Journal of Clinical Pharmacology, 2021, 77, 1815-1823.	1.9	2
60	Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?. European Heart Journal, 2021, 42, 3143-3145.	2.2	11
61	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. Atherosclerosis, 2021, 331, 38-44.	0.8	1
62	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 2726-2737.	3.8	17
63	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. International Journal of Cardiology, 2021, 337, 9-15.	1.7	4
64	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. Journal of the American College of Cardiology, 2021, 78, 859-866.	2.8	27
65	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1091-1102.	3.3	1
66	Ross for Valve replacement In Adults (REVIVAL) pilot trial: rationale and design of a randomised controlled trial. BMJ Open, 2021, 11, e046198.	1.9	4
67	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. JAMA Cardiology, 2021, 6, 1042.	6.1	35
68	Direct oral anticoagulant dose selection: Challenging cases. Journal of Thrombosis and Haemostasis, 2021, 19, 2680-2686.	3.8	4
69	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney International, 2021, 100, 1199-1207.	5.2	23
70	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. Europace, 2021, 23, 748-756.	1.7	7
71	Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	0
72	Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on-treatment platelet reactivity: the OPTimal Management of Antithrombotic Agents (OPTIMA)-2 Trial. British Journal of Haematology, 2021, , .	2.5	5

#	ARTICLE	IF	CITATIONS
73	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. JAMA Network Open, 2021, 4, e2141328.	5.9	30
74	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. JAMA Neurology, 2020, 77, 43.	9.0	54
75	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology, 2020, 27, 296-307.	1.8	28
76	Reply. Gastroenterology, 2020, 158, 1175-1176.	1.3	1
77	Reply. Gastroenterology, 2020, 158, 285-286.	1.3	0
78	Selection Bias, Orthopaedic Style. Journal of Bone and Joint Surgery - Series A, 2020, 102, 631-633.	3.0	10
79	Mortality benefits of thromboprophylaxis. Lancet Haematology,the, 2020, 7, e783.	4.6	0
80	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. European Heart Journal, 2020, 41, 4037-4046.	2.2	90
81	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2020, 76, 594-622.	2.8	187
82	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?â€”A Systematic Review. Thrombosis and Haemostasis, 2020, 120, 1323-1329.	3.4	22
83	Direct oral anticoagulants: evidence and unresolved issues. Lancet, The, 2020, 396, 1767-1776.	13.7	100
84	Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. Journal of the American College of Cardiology, 2020, 76, 2906-2907.	2.8	6
85	Is aspirin safer than a direct oral anticoagulant for patients with atrial fibrillation at high risk of bleeding?. European Journal of Internal Medicine, 2020, 79, 25-26.	2.2	0
86	Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. Future Cardiology, 2020, 16, 597-611.	1.2	0
87	Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial. Pilot and Feasibility Studies, 2020, 6, 104.	1.2	3
88	Cardiac Tamponade During Uninterrupted Oral Anticoagulant Therapy for Catheter Ablation for Atrial Fibrillation. JACC: Clinical Electrophysiology, 2020, 6, 796-798.	3.2	1
89	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke, 2020, 51, 2901-2909.	2.0	15
90	Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine, 2020, 383, 1838-1847.	27.0	1,010

#	ARTICLE	IF	CITATIONS
91	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. JAMA Network Open, 2020, 3, e2015943.	5.9	5
92	Trial Design Principles for Patients at Highâ€“Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	2.8	35
93	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e018984.	3.7	37
94	Fatty acid binding protein 3 is associated with peripheral arterial disease. JVS Vascular Science, 2020, 1, 168-175.	1.1	20
95	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. European Heart Journal, 2020, 41, 2848-2859.	2.2	25
96	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
97	Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors. Circulation, 2020, 141, 1690-1692.	1.6	0
98	The COMPASS Trial. Circulation, 2020, 142, 40-48.	1.6	83
99	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation, 2020, 141, 1141-1151.	1.6	39
100	Optimal Prescription of the Lower Dose of Apixaban. Journal of the American College of Cardiology, 2020, 75, 1156-1158.	2.8	0
101	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation, 2020, 141, 1841-1854.	1.6	96
102	Oral factor Xa inhibitors and risk of subdural hematoma. Neurology, 2020, 95, e480-e487.	1.1	1
103	Plasma Levels of Protein Z in Ischemic Stroke: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 815-822.	3.4	6
104	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer. Thrombosis and Haemostasis, 2020, 120, 194-196.	3.4	0
105	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	13.7	87
106	Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Thrombosis and Haemostasis, 2020, 120, 484-494.	3.4	22
107	Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and End-Stage Renal Diseaseâ€“First, Do No Harm. JAMA Network Open, 2020, 3, e202237.	5.9	10
108	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392

#	ARTICLE	IF	CITATIONS
109	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	2.7	13
110	The Ross procedure versus prosthetic and homograft aortic valve replacement: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 247-255.	1.4	21
111	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	5.9	11
112	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	1.3	299
113	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	2.8	95
114	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	1.3	108
115	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	2.3	11
116	Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 367, l5476.	2.3	66
117	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2019, 218, 46-56.	2.7	72
118	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <i>Stroke</i> , 2019, 50, 3347-3354.	2.0	32
119	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , 2019, 70, 1-7.	2.2	17
120	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007545.	4.8	25
121	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, 3771-3778a.	2.2	34
122	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
123	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	2.8	30
124	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1760-1768.	2.8	24
125	Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 668-674.	3.4	24
126	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	3.4	8

#	ARTICLE	IF	CITATIONS
127	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
128	Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2769-2772.	2.8	5
129	Pulmonary embolism: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019, 211, 82-87.	1.7	18
130	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	1.6	81
131	Deep vein thrombosis: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019, 210, 516-524.	1.7	73
132	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	2.2	335
133	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
134	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2360.	2.8	0
135	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2243-2250.	2.8	39
136	Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2846-2856.	1.6	11
137	External applicability of the COMPASS trial: the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 192-199.	3.0	12
138	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. <i>Blood</i> , 2019, 133, 2269-2278.	1.4	15
139	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44
140	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	27.0	687
141	Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion. <i>Transfusion</i> , 2019, 59, 1850-1856.	1.6	7
142	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 720-728.	27.0	520
143	Review: After PCI with DESs, long- and standard-term DAPT increase some adverse outcomes vs short-term DAPT. <i>Annals of Internal Medicine</i> , 2019, 171, JC54.	3.9	0
144	Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. <i>Future Cardiology</i> , 2019, 15, 395-404.	1.2	5

#	ARTICLE	IF	CITATIONS
145	Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy. The Cochrane Library, 2019, , .	2.8	3
146	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. American Heart Journal, 2019, 218, 100-109.	2.7	7
147	How Did We Get Here?: A Historical Review and Critical Analysis of Anticoagulation Therapy Following Mechanical Valve Replacement. Circulation, 2019, 140, 1933-1942.	1.6	15
148	The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. International Journal of Cardiology, 2019, 278, 7-13.	1.7	19
149	The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. Transfusion, 2019, 59, 482-491.	1.6	51
150	Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 1-11.	2.9	36
151	Stroke prevention in AF: Of Asians and non-Asians. European Heart Journal, 2019, 40, 1528-1530.	2.2	3
152	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the Atrial Fibrillation Registry Trial. Journal of the American Heart Association, 2019, 8, e010107.	3.7	17
153	Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2019, 119, 328-339.	3.4	8
154	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. Journal of the American College of Cardiology, 2019, 73, 121-130.	2.8	69
155	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. American Journal of Cardiology, 2019, 123, 153-158.	1.6	10
156	NOACs only for those who cannot tolerate a VKA: where is the evidence?. Acta Cardiologica, 2019, 74, 17-20.	0.9	0
157	How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?. Kardiologia Polska, 2019, 77, 661-669.	0.6	7
158	Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. Blood, 2019, 134, 711-711.	1.4	1
159	Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study. Blood, 2019, 134, 2434-2434.	1.4	3
160	International Normalized Ratio Targets for Left-Sided Mechanical Valve Replacement. Thrombosis and Haemostasis, 2018, 118, 906-913.	3.4	14
161	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	2.2	28
162	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). Canadian Journal of Cardiology, 2018, 34, 295-302.	1.7	25

#	ARTICLE	IF	CITATIONS
163	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq1 1 0.784314 rgBT /Overclock 10 T	2.2	92
164	Rivaroxaban with or without aspirin for prevention of cardiovascular disease. Coronary Artery Disease, 2018, 29, 361-365.	0.7	0
165	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia, 2018, 120, 645-656.	3.4	115
166	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. American Heart Journal, 2018, 198, 169-177.	2.7	14
167	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal, 2018, 39, 750-757a.	2.2	72
168	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2018, 71, 2306-2315.	2.8	296
169	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. American Heart Journal, 2018, 199, 59-67.	2.7	36
170	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	13.7	426
171	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	13.7	651
172	Anticoagulant-Related Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 2787-2793.	6.1	74
173	Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiology, 2018, 14, 443-453.	1.2	6
174	The value of novel oral anticoagulants in rural Australia. Medical Journal of Australia, 2018, 208, 15-16.	1.7	0
175	Response to: Unacceptable conflicts of interest (Br J Anaesth 2018; 121: 1183). British Journal of Anaesthesia, 2018, 121, 1183-1184.	3.4	0
176	In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. Thrombosis and Haemostasis, 2018, 118, 1895-1901.	3.4	8
177	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
178	Patients with Peripheral Artery Disease in the COMPASS Trial. European Journal of Vascular and Endovascular Surgery, 2018, 56, 772-773.	1.5	6
179	Direct Oral Anticoagulants and Myocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 27-28.	2.8	5
180	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2018, 138, 527-536.	1.6	211

#	ARTICLE	IF	CITATIONS
181	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018, 39, 3973-3979.	2.2	131
182	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	2.8	56
183	Hemodynamic outcomes of the Ross procedure versus other aortic valve replacement: a systematic review and meta-analysis. <i>Journal of Cardiovascular Surgery</i> , 2018, 59, 462-470.	0.6	15
184	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 2325-2334.	13.7	236
185	Reduced-Intensity Anticoagulation for Mechanical Aortic Valve Prostheses. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2727-2730.	2.8	4
186	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. <i>European Journal of Haematology</i> , 2018, 101, 362-367.	2.2	5
187	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	2.5	80
188	Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 310-315.	2.1	2
189	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	1.4	12
190	Dual and triple antithrombotic therapies: current patterns of practice and controversies. <i>Kardiologia Polska</i> , 2018, 76, 937-944.	0.6	1
191	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	2.2	106
192	Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. <i>Vox Sanguinis</i> , 2017, 112, 268-278.	1.5	43
193	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	2.9	78
194	Clinical implications of reversal agents for direct oral anticoagulants. <i>Future Cardiology</i> , 2017, 13, 153-159.	1.2	7
195	Is There a Role for Betrixaban to Prevent Stroke in Medically Ill Patients?. <i>Circulation</i> , 2017, 135, 656-658.	1.6	2
196	Anticoagulation for Mechanical Heart Valves. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 743-745.	2.4	17
197	Resuming warfarin after intracranial hemorrhage in patients with AF was linked to reduced mortality. <i>Annals of Internal Medicine</i> , 2017, 166, JC70.	3.9	0
198	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	2.7	42

#	ARTICLE	IF	CITATIONS
199	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	1.7	133
200	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. JAMA Cardiology, 2017, 2, 566.	6.1	106
201	Short-Term versus Long-Term Blood Storage. New England Journal of Medicine, 2017, 376, 1091-1094.	27.0	5
202	Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Thrombolysis, 2017, 43, 291-301.	2.1	35
203	A Test in Context: D-Dimer. Journal of the American College of Cardiology, 2017, 70, 2411-2420.	2.8	342
204	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. Lancet Haematology, 2017, 4, e544-e552.	4.6	34
205	HERDOO2 identified women at low risk for recurrence after 5 to 12 mo of anticoagulation for a first unprovoked VTE. Annals of Internal Medicine, 2017, 167, JC33.	3.9	1
206	Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. CMAJ Open, 2017, 5, E594-E603.	2.4	6
207	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	27.0	1,745
208	Aortic valve replacement in younger patients. European Heart Journal, 2017, 38, 3378-3381.	2.2	7
209	Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. Thrombosis Research, 2017, 157, 165-166.	1.7	9
210	Platelet Transfusion for Ticagrelor Reversal. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	8
211	In Reply. Anesthesiology, 2017, 127, 401-402.	2.5	0
212	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2017, 70, 3042-3067.	2.8	285
213	Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. New England Journal of Medicine, 2017, 377, 431-441.	27.0	858
214	Which Patients With Atrial Fibrillation and Chronic Kidney Disease Should Receive Anticoagulation? And With Which Anticoagulant?. Canadian Journal of Cardiology, 2017, 33, 211-213.	1.7	4
215	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Thrombosis and Haemostasis, 2017, 117, 2135-2145.	3.4	53
216	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. TH Open, 2017, 01, e139-e145.	1.4	31

#	ARTICLE	IF	CITATIONS
217	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. <i>Journal of Cardiovascular Surgery</i> , 2017, 59, 128-139.	0.6	8
218	Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. <i>TH Open</i> , 2017, 01, e82-e91.	1.4	13
219	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 257-270.	3.4	11
220	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	3.4	34
221	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	3.4	34
222	Quantification of Cell-Free DNA in Red Blood Cell Units in Different Whole Blood Processing Methods. <i>Journal of Blood Transfusion</i> , 2016, 2016, 1-5.	3.3	14
223	Laboratory measurement of the direct oral anticoagulants. <i>British Journal of Haematology</i> , 2016, 172, 315-336.	2.5	79
224	Exposure to ABO nonidentical blood associated with increased in-hospital mortality in patients with group A blood. <i>Transfusion</i> , 2016, 56, 550-557.	1.6	18
225	How good is aspirin for patients with acute brain ischaemia?. <i>Nature Reviews Neurology</i> , 2016, 12, 434-435.	10.1	0
226	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016, 220, 417-428.	1.7	9
227	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	1.6	19
228	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , The, 2016, 387, 2302-2311.	13.7	389
229	Rapid reversal of haematoma expansion associated with vitamin K antagonists. <i>Lancet Neurology</i> , The, 2016, 15, 535-537.	10.2	4
230	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	5.8	40
231	Advances in Thrombosis and Hemostasis. <i>Circulation Research</i> , 2016, 118, 1337-1339.	4.5	12
232	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	4.5	96
233	Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995–2010. <i>International Journal of Cardiology</i> , 2016, 208, 19-25.	1.7	40
234	Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2016, 129, e35-e36.	1.5	29

#	ARTICLE	IF	CITATIONS
235	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. American Heart Journal, 2016, 178, 145-150.	2.7	52
236	Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood, 2016, 127, 400-410.	1.4	94
237	Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. American Journal of Medicine, 2016, 129, S33-S40.	1.5	74
238	Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. American Journal of Medicine, 2016, 129, e247-e248.	1.5	13
239	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. American Journal of Emergency Medicine, 2016, 34, 3-8.	1.6	25
240	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics, 2016, 17, 1425-1439.	1.3	21
241	Ciraparantag for enoxaparin reversal: Adding to the evidence. Thrombosis Research, 2016, 146, 106-107.	1.7	6
242	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation, 2016, 134, 1697-1707.	1.6	76
243	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2016, 375, 1131-1141.	27.0	692
244	Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". Circulation, 2016, 134, e498.	1.6	0
245	Appropriate Apixaban Dosing. JAMA Cardiology, 2016, 1, 635.	6.1	16
246	Urgent Need to Measure Effects of Direct Oral Anticoagulants. Circulation, 2016, 134, 186-188.	1.6	47
247	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. New England Journal of Medicine, 2016, 375, 1937-1945.	27.0	278
248	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	83
249	Perioperative Aspirin for Prevention of Venous Thromboembolism. Anesthesiology, 2016, 125, 1121-1129.	2.5	22
250	Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study. European Journal of Internal Medicine, 2016, 33, 55-59.	2.2	25
251	Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. Canadian Journal of Cardiology, 2016, 32, 1108-1116.	1.7	6
252	Letter to the Editor. Journal of Intensive Care Medicine, 2016, 31, 70-71.	2.8	0

#	ARTICLE	IF	CITATIONS
253	Enhanced TRAP-induced platelet aggregation with dabigatran â€” Clinical perspective. <i>Thrombosis Research</i> , 2016, 138, 61-62.	1.7	0
254	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	2.9	34
255	Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 90-98.	2.1	9
256	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1300-1308.	2.8	154
257	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	1.7	29
258	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1332-1339.	1.7	7
259	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , 2016, 30, 25-29.	2.0	15
260	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	2.2	69
261	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016, 140, 81-88.	1.7	14
262	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. <i>Lancet Haematology</i> , 2016, 3, e246-e254.	4.6	57
263	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	1.7	19
264	Association of cardiac biomarkers with acute kidney injury after cardiac surgery: A multicenter cohort study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 245-251.e4.	0.8	35
265	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. <i>American Heart Journal</i> , 2016, 173, 102-107.	2.7	34
266	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016, 45, 77-83.	1.6	91
267	Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study. <i>Blood</i> , 2016, 128, 2617-2617.	1.4	2
268	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2682.	2.8	1
269	Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 96.	1.7	108
270	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	3.4	201

#	ARTICLE	IF	CITATIONS
271	Exploratory studies on the age of transfused blood and in-hospital mortality in patients with cardiovascular diagnoses. <i>Transfusion</i> , 2015, 55, 364-372.	1.6	25
272	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1049-1057.	3.4	26
273	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2015, 114, 933-944.	3.4	11
274	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. <i>Vascular Health and Risk Management</i> , 2015, 11, 343.	2.3	68
275	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 768-777.	3.4	33
276	Timing the First Postoperative Dose of Anticoagulants. <i>Chest</i> , 2015, 148, 587-595.	0.8	15
277	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	3.4	132
278	“Real world” use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1159-1161.	3.4	18
279	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	2.8	197
280	Idarucizumab. <i>Circulation</i> , 2015, 132, 2412-2422.	1.6	141
281	Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials. <i>Thrombosis Research</i> , 2015, 136, 1087-1098.	1.7	17
282	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015, 36, 281-288.	2.2	253
283	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 231-239.	2.1	32
284	Mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation. <i>Annals of Internal Medicine</i> , 2015, 162, JC4.	3.9	0
285	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 796-803.	1.6	90
286	Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery. <i>Kidney International</i> , 2015, 88, 576-583.	5.2	25
287	Intensity and Quality of Warfarin Anticoagulation in Chinese Patients. <i>Stroke</i> , 2015, 46, 5-6.	2.0	6
288	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	27.0	1,419

#	ARTICLE	IF	CITATIONS
289	Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 618-627.	5.1	61
290	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , 2015, 36, 1454-1462.	2.2	106
291	Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. <i>Pediatric Nephrology</i> , 2015, 30, 1519-1527.	1.7	62
292	Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin. <i>Evidence-Based Medicine</i> , 2015, 20, 117-117.	0.6	0
293	Cardiac Biomarkers and Acute Kidney Injury After Cardiac Surgery. <i>Pediatrics</i> , 2015, 135, e945-e956.	2.1	53
294	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1213-1223.	1.5	1
295	Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3123-3132.	6.1	144
296	Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 23-34.	2.1	25
297	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. <i>Cardiology Research</i> , 2015, 6, 267-277.	1.1	1
298	Management of bleeding with oral anticoagulants in patients with atrial fibrillation. <i>Hamostaseologie</i> , 2015, 35, 351-357.	1.9	1
299	Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. <i>Thrombosis and Haemostasis</i> , 2014, 112, 918-923.	3.4	58
300	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , 2014, 111, 10-13.	3.4	10
301	Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1120-1128.	3.4	17
302	Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Trial." <i>Circulation</i> , 2014, 129, 1111-1112.	1.1	1
303	Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. <i>Future Cardiology</i> , 2014, 10, 43-52.	1.2	33
304	Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin." <i>Circulation</i> , 2014, 130, e95.	1.6	0
305	Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study." <i>Circulation</i> , 2014, 130, e85.	1.6	3
306	Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2014, 29, 1-9.	1.8	7

#	ARTICLE	IF	CITATIONS
307	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014, 35, 1856-1863.	2.2	28
308	Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. <i>European Heart Journal</i> , 2014, 35, 1831-1833.	2.2	12
309	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <i>Thrombosis and Haemostasis</i> , 2014, 111, 798-807.	3.4	48
310	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 321-328.	2.8	733
311	Efficacy and Safety of Warfarin VS. Antiplatelet Therapy in Patients with Systolic Heart Failure and Sinus Rhythm: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>International Journal of Stroke</i> , 2014, 9, 199-206.	5.9	13
312	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2885-2886.	2.8	5
313	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 435-442.	2.1	10
314	A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. <i>European Journal of Epidemiology</i> , 2014, 29, 181-190.	5.7	99
315	Aspirin in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1494-1503.	27.0	735
316	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	1.6	346
317	Clonidine in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1504-1513.	27.0	285
318	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	2.2	42
319	Novel Oral Anticoagulants: A Focused Review for Stroke Physicians. <i>International Journal of Stroke</i> , 2014, 9, 71-78.	5.9	12
320	Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 362-371.	2.1	15
321	Colchicine for Secondary Prevention of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2014, 16, 391.	4.8	31
322	Targeting Cholesterol Crystal-Induced Inflammation for the Secondary Prevention of Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 45-52.	2.0	38
323	Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? <i>American Journal of Emergency Medicine</i> , 2014, 32, 1433-1434.	1.6	1
324	Immature Platelet Count. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2130-2132.	2.8	8

#	ARTICLE	IF	CITATIONS
325	Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 3637-3642.	2.0	19
326	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014, 124, 689-699.	1.4	28
327	Aspirin for the Prevention of Recurrent Venous Thromboembolism. <i>Circulation</i> , 2014, 130, 1062-1071.	1.6	232
328	The mTORC Pathway in the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 369-371.	27.0	16
329	Switching Patients From Blinded Study Drug to Warfarin at the End of the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2014, 64, 585-587.	2.8	6
330	Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update. <i>Neurology: Clinical Practice</i> , 2014, 4, 96-98.	1.6	3
331	Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 2127-2130.	2.0	11
332	Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. <i>BMJ Open</i> , 2014, 4, e005674-e005674.	1.9	3
333	Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent. <i>Canadian Journal of Cardiology</i> , 2014, 30, 381-384.	1.7	20
334	Myocardial Injury after Noncardiac Surgery. <i>Anesthesiology</i> , 2014, 120, 564-578.	2.5	740
335	Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. <i>Annals of Internal Medicine</i> , 2014, 160, JC4.	3.9	0
336	Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study. <i>Blood</i> , 2014, 124, 343-343.	1.4	2
337	Utilization of Universal Group O Blood By Non Group O Recipients. <i>Blood</i> , 2014, 124, 5103-5103.	1.4	1
338	Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. <i>PLoS ONE</i> , 2014, 9, e88131.	2.5	11
339	Approach to the new oral anticoagulants in family practice: part 1: comparing the options. <i>Canadian Family Physician</i> , 2014, 60, 989-95.	0.4	12
340	Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. <i>Canadian Family Physician</i> , 2014, 60, 997-1001.	0.4	10
341	New oral anticoagulants in elderly patients. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 215-224.	1.7	60
342	Novel Oral Anticoagulants for Atrial Fibrillation. <i>Current Atherosclerosis Reports</i> , 2013, 15, 344.	4.8	14

#	ARTICLE	IF	CITATIONS
343	Targeting the Unstable Plaque in Acute Coronary Syndromes. <i>Clinical Therapeutics</i> , 2013, 35, 1099-1107.	2.5	20
344	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. <i>New England Journal of Medicine</i> , 2013, 369, 1206-1214.	27.0	1,201
345	Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1042-1047.	1.7	19
346	Adherence to anticoagulant treatment with dabigatran in a real-world setting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1295-1299.	3.8	91
347	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
348	Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S34-S44.	1.7	40
349	Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2013, 29, S71-S78.	1.7	75
350	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	27.0	4,215
351	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013, 128, 237-243.	1.6	195
352	The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. <i>BMC Geriatrics</i> , 2013, 13, 88.	2.7	39
353	Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. <i>Cardiology and Therapy</i> , 2013, 2, 135-149.	2.6	37
354	Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. <i>Circulation</i> , 2013, 127, 1404-1412.	1.6	222
355	Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. <i>Circulation</i> , 2013, 127, 634-640.	1.6	447
356	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 295-301.	2.1	59
357	Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 404-410.	2.8	749
358	Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS ₂ and CHA ₂ DS ₂ -VASc Scores in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 31-38.	4.8	23
359	Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. <i>Thrombosis Research</i> , 2013, 131, 300-303.	1.7	2
360	Pacemaker-Detected Atrial Fibrillation in Patients With Pacemakers: Prevalence, Predictors, and Current Use of Oral Anticoagulation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 224-228.	1.7	83

#	ARTICLE	IF	CITATIONS
361	Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 900-908.	2.8	59
362	Procoagulants for management of bleeding with the new oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2013, 110, 01.	3.4	11
363	Anticoagulant therapy in acute brain ischaemia. <i>Lancet Neurology</i> , The, 2013, 12, 526-527.	10.2	8
364	Anti- α 2 μ PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 253-260.	3.8	14
365	Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding. <i>Circulation</i> , 2013, 128, 1179-1181.	1.6	47
366	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013, 34, 170-176.	2.2	160
367	Aspirin for Preventing Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 772-773.	27.0	5
368	Atrial fibrillation is associated with increased mortality: causation or association?. <i>European Heart Journal</i> , 2013, 34, 1027-1030.	2.2	40
369	Effect of B Vitamins and Lowering Homocysteine on Cognitive Impairment in Patients With Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2013, 44, 2232-2239.	2.0	67
370	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , 2013, 34, 2752-2759.	2.2	21
371	Stroke prevention in older adults with atrial fibrillation. <i>Cmaj</i> , 2013, 185, 1479-1480.	2.0	6
372	Response to Letters Regarding Article, "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial". <i>Circulation</i> , 2013, 127, e506.	1.6	2
373	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 2192-2201.	1.6	268
374	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <i>European Heart Journal</i> , 2013, 34, 1498-1505.	2.2	109
375	Direct-Acting Oral Anticoagulants. <i>JAMA Neurology</i> , 2013, 70, 1483-4.	9.0	6
376	Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 778-782.	3.8	10
377	A guide to GRADE guidelines for the readers of JTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1603-1608.	3.8	32
378	Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial. <i>Transfusion</i> , 2013, 53, 1487-1492.	1.6	9

#	ARTICLE	IF	CITATIONS
379	A response to - There's madness in their methods. Journal of Thrombosis and Haemostasis, 2013, 11, 785-786.	3.8	0
380	Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology, 2013, 81, 825-832.	1.1	107
381	Dabigatran monitoring made simple?. Thrombosis and Haemostasis, 2013, 110, 393-395.	3.4	9
382	Is there really misuse and abuse of dabigatran?. Medical Journal of Australia, 2013, 198, 358-359.	1.7	4
383	Venous Thrombosis. , 2013, , 619-626.		0
384	Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. Blood, 2013, 122, 3651-3651.	1.4	6
385	Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. Circulation, 2012, 126, 2309-2316.	1.6	133
386	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation, 2012, 125, 669-676.	1.6	348
387	The aspirin controversy in primary prevention. Current Opinion in Cardiology, 2012, 27, 499-507.	1.8	25
388	Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. Current Opinion in Cardiology, 2012, 27, 331-339.	1.8	9
389	Antithrombotic Therapy After Coronary Artery Stenting in Patients With Atrial Fibrillation. Circulation: Cardiovascular Interventions, 2012, 5, 454-455.	3.9	0
390	Effect of <i>PON1</i> Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. Circulation: Cardiovascular Genetics, 2012, 5, 250-256.	5.1	25
391	More on Acutely Injured Patients Receiving Dabigatran. New England Journal of Medicine, 2012, 366, 863-864.	27.0	5
392	Anticoagulants in Patients with Atrial Fibrillation and End-Stage Renal Disease. Postgraduate Medicine, 2012, 124, 17-25.	2.0	10
393	Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. Expert Review of Cardiovascular Therapy, 2012, 10, 965-972.	1.5	12
394	Reply to Letters Regarding Article, "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial" Circulation, 2012, 125, .	1.6	2
395	Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. Circulation, 2012, 126, 2428-2432.	1.6	105
396	Sex, Stroke, and Atrial Fibrillation. Archives of Neurology, 2012, 69, 1641.	4.5	14

#	ARTICLE	IF	CITATIONS
397	Treatment With B Vitamins and Incidence of Cancer in Patients With Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2012, 43, 1572-1577.	2.0	20
398	Letter by Van de Werf et al Regarding Article, "Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians" <i>Stroke</i> , 2012, 43, e46-7; author reply e49.	2.0	0
399	B Vitamins and Magnetic Resonance Imaging-Detected Ischemic Brain Lesions in Patients With Recent Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2012, 43, 3266-3270.	2.0	72
400	The hazards of interrupting anticoagulation therapy in atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 1864-1866.	2.2	12
401	Which Risk Factors Are More Associated With Ischemic Stroke Than Intracerebral Hemorrhage in Patients With Atrial Fibrillation?. <i>Stroke</i> , 2012, 43, 2048-2054.	2.0	36
402	New Antithrombotic Drugs. <i>Chest</i> , 2012, 141, e120S-e151S.	0.8	284
403	REVERSAL OF THE ANTI-PLATELET EFFECTS OF ASPIRIN AND CLOPIDOGREL. <i>Heart</i> , 2012, 98, E272.2-E272.	2.9	0
404	Approach to Outcome Measurement in the Prevention of Thrombosis in Surgical and Medical Patients. <i>Chest</i> , 2012, 141, e185S-e194S.	0.8	161
405	Idrabiotaparinux treatment for venous thromboembolism. <i>Lancet</i> , The, 2012, 379, 96-98.	13.7	2
406	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012, 33, 2143-2150.	2.2	86
407	Translational Success Stories. <i>Circulation Research</i> , 2012, 111, 920-929.	4.5	61
408	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. <i>Lancet Neurology</i> , The, 2012, 11, 1066-1081.	10.2	75
409	Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 429-436.	2.1	13
410	Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 429-435.	1.6	94
411	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 944-950.e3.	0.8	13
412	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012, 129, 715-719.	1.7	37
413	Aspirin response variability after major orthopedic surgery. <i>Thrombosis Research</i> , 2012, 130, 216-220.	1.7	13
414	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012, 119, 2172-2174.	1.4	219

#	ARTICLE	IF	CITATIONS
415	Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. <i>Stroke</i> , 2012, 43, 3291-3297.	2.0	83
416	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfeTy and pharmacokinetics of oral dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). <i>American Heart Journal</i> , 2012, 163, 931-937.e1.	2.7	164
417	Dabigatran for patients with a mechanical valve. <i>Heart Lung and Circulation</i> , 2012, 21, 121.	0.4	0
418	Should Warfarin Be Restarted After Warfarin-Associated Intracranial Hemorrhage?. <i>Canadian Journal of Cardiology</i> , 2012, 28, 6-8.	1.7	0
419	Dabigatran and risk of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012, 9, 260-262.	13.7	30
420	Anticoagulants in atrial fibrillation patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 569-578.	9.6	72
421	Prevention of Thromboembolic Events After Bioprosthetic Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2012, 60, 978-980.	2.8	15
422	Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2012, 367, 1979-1987.	27.0	453
423	The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2012, 107, 998-1000.	3.4	7
424	Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. <i>Thrombosis and Haemostasis</i> , 2012, 107, 8-14.	3.4	14
425	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235.	3.4	24
426	Direct thrombin inhibitors in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2012, 9, 402-414.	13.7	30
427	Warfarin in Heart Failure. <i>New England Journal of Medicine</i> , 2012, 366, 1936-1938.	27.0	11
428	Antiplatelet Drugs. <i>Chest</i> , 2012, 141, e89S-e119S.	0.8	318
429	Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. <i>Chest</i> , 2012, 141, 53S-70S.	0.8	213
430	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. <i>Circulation</i> , 2012, 126, 343-348.	1.6	494
431	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. <i>Journal of Internal Medicine</i> , 2012, 271, 15-24.	6.0	48
432	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology</i> , The, 2012, 11, 225-231.	10.2	164

#	ARTICLE	IF	CITATIONS
433	Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 512-520.	10.2	70
434	Reducing the risk of recurrent stroke in patients with AF. <i>Lancet Neurology</i> , The, 2012, 11, 479-481.	10.2	2
435	The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. <i>Transfusion</i> , 2012, 52, 1203-1212.	1.6	61
436	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. <i>Transfusion</i> , 2012, 52, 1363-1378.	1.6	11
437	Old blood bad? Either the biggest issue in transfusion medicine or a nonevent. <i>Transfusion</i> , 2012, 52, 1165-1167.	1.6	3
438	Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 229-235.	3.8	24
439	Reversal of the antiplatelet effects of aspirin and clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 521-528.	3.8	119
440	Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 966-968.	3.8	9
441	The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?. <i>International Journal of Stroke</i> , 2012, 7, 139-141.	5.9	6
442	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. <i>American Journal of Hematology</i> , 2012, 87, S100-7.	4.1	5
443	Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 17-23.	4.2	8
444	Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 88-94.	2.1	99
445	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. <i>Blood</i> , 2012, 120, 19-19.	1.4	7
446	The reemergence of aspirin for the prevention of venous thromboembolism. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 120-1.	0.3	3
447	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 279-286.	1.5	15
448	Dabigatran Etxilate. <i>Circulation</i> , 2011, 123, 1436-1450.	1.6	340
449	Overexpression of the Multidrug Resistance Protein-4 Transporter in Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 58, 762-764.	2.8	10
450	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	27.0	2,207

#	ARTICLE	IF	CITATIONS
451	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. <i>Thrombosis and Haemostasis</i> , 2011, 106, 571-584.	3.4	188
452	Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2011, 124, 621-629.	1.5	134
453	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. <i>Canadian Journal of Cardiology</i> , 2011, 27, 711-715.	1.7	11
454	Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. <i>Annual Review of Medicine</i> , 2011, 62, 41-57.	12.2	177
455	Apixaban in Acute Coronary Syndromes. <i>Cardiovascular Therapeutics</i> , 2011, 29, 285-290.	2.5	5
456	Double-dose clopidogrel in patients undergoing PCI for ACS â€œ Authors' reply. <i>Lancet, The</i> , 2011, 377, 298.	13.7	1
457	Should adult patients be routinely tested for heritable thrombophilia after an episode of venous thromboembolism?. <i>Medical Journal of Australia</i> , 2011, 195, 139-142.	1.7	6
458	New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 777-782.	0.5	0
459	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS ₂ Score: A Subgroup Analysis of the RE-LY Trial. <i>Annals of Internal Medicine</i> , 2011, 155, 660.	3.9	181
460	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. <i>Annals of Internal Medicine</i> , 2011, 155, 579.	3.9	119
461	Fondaparinux treatment of acute heparinâ€induced thrombocytopenia confirmed by the serotoninâ€release assay: a 30â€month, 16â€patient case series. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2389-2396.	3.8	127
462	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 378-385.	2.1	14
463	Chills and limb pain following administration of lowâ€molecularâ€weight heparin for treatment of acute venous thromboembolism. <i>American Journal of Hematology</i> , 2011, 86, 603-606.	4.1	11
464	Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials. <i>Blood Reviews</i> , 2011, 25, 123-129.	5.7	39
465	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ: British Medical Journal</i> , 2011, 342, c7270-c7270.	2.3	13
466	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
467	Importance of Family History as a Risk Factor for Venous Thromboembolism. <i>Circulation</i> , 2011, 124, 996-997.	1.6	10
468	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 522-534.	3.9	103

#	ARTICLE	IF	CITATIONS
469	Validity of Composite Outcomes in Meta-Analyses of Stroke Prevention Trials: The Case of Aspirin. <i>Cerebrovascular Diseases</i> , 2011, 32, 22-27.	1.7	7
470	New oral anticoagulants for stroke prevention in atrial fibrillation. <i>Clinical Investigation</i> , 2011, 1, 3-7.	0.0	3
471	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 2256-2265.	2.2	41
472	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	2.2	343
473	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	1.6	1,035
474	Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 505-513.	3.9	16
475	CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 514-521.	3.9	19
476	Oral antiplatelet therapy. , 2011, , 311-319.		0
477	The Use of Platelet Function Assays May Help to Determine Appropriate Antiplatelet Treatment Options in a Patient With Recurrent Stroke on Baby Aspirin. <i>Stroke</i> , 2010, 41, 2398-2399.	2.0	16
478	Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease. <i>Future Cardiology</i> , 2010, 6, 289-299.	1.2	9
479	Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 127-132.	2.1	24
480	Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 434-440.	2.1	29
481	Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. <i>Lancet Neurology</i> , The, 2010, 9, 273-284.	10.2	83
482	B vitamins in patients with recent transient ischaemic attack or stroke in the VITamins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 855-865.	10.2	264
483	A National Survey of Canadian Practice Patterns of Warfarin After Anterior Wall Myocardial Infarction in the Current Era of Dual Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2010, 105, 1844.	1.6	5
484	Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 148-156.	3.8	813
485	Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 101-106.	3.8	77
486	Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 243-249.	3.8	39

#	ARTICLE	IF	CITATIONS
487	How can we reduce disagreement among guidelines for venous thromboembolism prevention?. Journal of Thrombosis and Haemostasis, 2010, 8, 675-677.	3.8	4
488	Does dabigatran improve stroke-prevention in atrial fibrillation? Reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2010, 8, 1438-1439.	3.8	3
489	A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. Journal of Thrombosis and Haemostasis, 2010, 8, 1966-1975.	3.8	68
490	Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Medical Journal of Australia, 2010, 192, 487-488.	1.7	2
491	The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?. Thrombosis and Haemostasis, 2010, 104, 45-48.	3.4	124
492	Explaining the RE-LY Trial. Canadian Journal of Hospital Pharmacy, 2010, 63, 334-6.	0.1	0
493	Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. Thrombosis and Haemostasis, 2010, 103, 481-483.	3.4	6
494	Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 382-387.	2.4	36
495	Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. Circulation, 2010, 121, 1188-1199.	1.6	419
496	Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents. Circulation, 2010, 121, 2067-2070.	1.6	110
497	New Anticoagulants. Circulation, 2010, 121, 1523-1532.	1.6	262
498	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. European Heart Journal, 2010, 31, 50-58.	2.2	81
499	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine, 2010, 363, 930-942.	27.0	681
500	Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine, 2010, 363, 1704-1714.	27.0	497
501	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thrombosis Research, 2010, 125, e128-e131.	1.7	11
502	Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal, 2010, 159, 348-353.e1.	2.7	146
503	Duration of red cell storage before transfusion and in-hospital mortality. American Heart Journal, 2010, 159, 737-743.e1.	2.7	101
504	Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. American Heart Journal, 2010, 160, 1178-1184.	2.7	91

#	ARTICLE	IF	CITATIONS
505	Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. American Heart Journal, 2010, 160, 1049-1055.	2.7	15
506	DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS. Journal of the American College of Cardiology, 2010, 55, A1.E2.	2.8	9
507	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, The, 2010, 376, 1233-1243.	13.7	725
508	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, The, 2010, 376, 975-983.	13.7	913
509	New antithrombotic agentsâ€™ insights from clinical trials. Nature Reviews Cardiology, 2010, 7, 498-509.	13.7	45
510	Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools.. Blood, 2010, 116, 3800-3800.	1.4	1
511	Dabigatran: ready for prime time?. Polish Archives of Internal Medicine, 2010, 120, 137-142.	0.4	2
512	Duration of anticoagulant therapy for venous thromboembolism. Medical Journal of Australia, 2009, 190, 659-660.	1.7	4
513	Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction. Archives of Internal Medicine, 2009, 169, 1163.	3.8	6
514	Anticoagulation for ST-Segment Elevation Myocardial Infarction. Circulation, 2009, 119, 1186-1188.	1.6	5
515	Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials. Circulation, 2009, 120, 2006-2011.	1.6	74
516	Accelerated Infusion of Streptokinase for the Treatment of Left-Sided Prosthetic Valve Thrombosis. Circulation, 2009, 120, 1108-1114.	1.6	66
517	Effect of Long-Term Homocysteine Reduction with B Vitamins on Arterial Wall Inflammation Assessed by Fluorodeoxyglucose Positron Emission Tomography: A Randomised Double-Blind, Placebo-Controlled Trial. Cerebrovascular Diseases, 2009, 27, 259-265.	1.7	33
518	Response to Letter Regarding Article, â€œIncomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Riskâ€. Circulation, 2009, 119, .	1.6	3
519	New Anticoagulants for Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2009, 35, 515-524.	2.7	51
520	New Anticoagulants for Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2009, 35, 711-711.	2.7	0
521	Ethnicity Does Not Affect the Homocysteine-Lowering Effect of B-Vitamin Therapy in Singaporean Stroke Patients. Stroke, 2009, 40, 2209-2211.	2.0	7
522	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. American Journal of Hematology, 2009, 84, 579-583.	4.1	28

#	ARTICLE	IF	CITATIONS
523	New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. <i>Advances in Therapy</i> , 2009, 26, 1058-1071.	2.9	8
524	Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. <i>British Journal of Haematology</i> , 2009, 146, 142-149.	2.5	39
525	Postoperative Low Molecular Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 378-382.	1.2	92
526	Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. <i>Thrombosis Research</i> , 2009, 123, 687-696.	1.7	300
527	Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. <i>American Heart Journal</i> , 2009, 157, 60.e1-60.e9.	2.7	17
528	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. <i>American Heart Journal</i> , 2009, 158, 881-886.e1.	2.7	32
529	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	27.0	9,839
530	Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 241-249.	1.5	5
531	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. <i>Canadian Journal of Cardiology</i> , 2009, 25, 683-689.	1.7	78
532	Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. <i>Lancet, The</i> , 2009, 374, 565-576.	13.7	188
533	Otamixaban in acute coronary syndromes. <i>Lancet, The</i> , 2009, 374, 762-764.	13.7	8
534	Rivaroxaban versus enoxaparin after total knee arthroplasty. <i>Lancet, The</i> , 2009, 374, 681.	13.7	3
535	Anticoagulants for patients with prosthetic heart valves – Authors' reply. <i>Lancet, The</i> , 2009, 374, 1499-1500.	13.7	0
536	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. <i>Annals of Internal Medicine</i> , 2009, 150, 379.	3.9	152
537	American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ. <i>Chest</i> , 2009, 135, 513-520.	0.8	200
538	Deep Vein Thrombosis Prophylaxis: Response. <i>Chest</i> , 2009, 136, 1700-1701.	0.8	3
539	Percutaneous closure of the left atrial appendage was noninferior to warfarin in atrial fibrillation. <i>Annals of Internal Medicine</i> , 2009, 151, JC5.	3.9	0
540	Treatment of intermittent claudication. <i>BMJ: British Medical Journal</i> , 2009, 338, b46-b46.	2.3	2

#	ARTICLE	IF	CITATIONS
541	Dabigatran etexilate for prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009, 101, 2-4.	3.4	25
542	New oral anticoagulants: not quite there yet. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 53-59.	0.4	7
543	Clinical factors influencing the sensitivity to warfarin when restarted after surgery. <i>Journal of Internal Medicine</i> , 2008, 263, 412-419.	6.0	14
544	The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2008, 8, 24.	1.7	54
545	What do the results of the PROFESS trial teach us?. <i>Lancet Neurology</i> , The, 2008, 7, 860-862.	10.2	8
546	Clopidogrel Resistance. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1935-1937.	2.8	15
547	The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy—Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1978-1980.	2.8	4
548	Guidelines for anticoagulant use in acute coronary syndromes. <i>Lancet</i> , The, 2008, 371, 1559-1561.	13.7	14
549	Selective factor Xa inhibition for thromboprophylaxis. <i>Lancet</i> , The, 2008, 372, 6-8.	13.7	12
550	Guidelines for anticoagulant use in acute coronary syndromes — Authors' reply. <i>Lancet</i> , The, 2008, 372, 533-534.	13.7	1
551	Gastrointestinal bleeding after acute ischemic stroke. <i>Neurology</i> , 2008, 71, 650-655.	1.1	70
552	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 766-780.	3.3	80
553	Homocysteine or Renal Impairment. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1158-1164.	2.4	63
554	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. <i>Circulation</i> , 2008, 118, 2029-2037.	1.6	789
555	Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1638-1646.	2.0	47
556	The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. <i>European Heart Journal</i> , 2008, 29, 1057-1071.	2.2	138
557	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2008, 30, 655-661.	2.2	149
558	Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation". <i>Circulation</i> , 2008, 117, .	1.6	0

#	ARTICLE	IF	CITATIONS
559	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2008, 118, 2038-2046.	1.6	98
560	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. <i>Circulation</i> , 2008, 118, 1705-1712.	1.6	210
561	Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. <i>Country Review Ukraine</i> , 2008, 10, C8-C13.	0.8	12
562	The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. <i>Current Opinion in Cardiology</i> , 2008, 23, 327-334.	1.8	16
563	Management of peripheral arterial disease in the elderly: focus on cilostazol. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 17-23.	2.9	11
564	The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. <i>Medical Journal of Australia</i> , 2008, 189, 144-147.	1.7	75
565	Will prasugrel supersede clopidogrel for acute coronary syndromes?. <i>Medical Journal of Australia</i> , 2008, 188, 381-382.	1.7	5
566	Using aspirin to prevent cognitive decline. <i>BMJ: British Medical Journal</i> , 2008, 337, a958-a958.	2.3	5
567	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2007, 28, 1193-1204.	2.2	253
568	A Replacement for Warfarin. <i>Circulation</i> , 2007, 116, 131-133.	1.6	40
569	Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. <i>Circulation</i> , 2007, 116, 449-455.	1.6	82
570	Inherited thrombophilia and pregnancy associated venous thromboembolism. <i>BMJ: British Medical Journal</i> , 2007, 334, 1318-1321.	2.3	42
571	Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. <i>New England Journal of Medicine</i> , 2007, 357, 217-227.	27.0	383
572	Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter. <i>New England Journal of Medicine</i> , 2007, 356, 1071-1073.	27.0	4
573	Platelet Function Testing: Quality Assurance. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 273-282.	2.7	64
574	Latest medical treatment strategies for venous thromboembolism. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1221-1233.	1.8	10
575	Antithrombotic treatment for peripheral arterial disease. <i>Heart</i> , 2007, 93, 303-308.	2.9	19
576	Beyond Unfractionated Heparin and Warfarin. <i>Circulation</i> , 2007, 116, 552-560.	1.6	202

#	ARTICLE	IF	CITATIONS
577	Pexelizumab Does Not “Complement” Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2007, 297, 91.	7.4	7
578	Pexelizumab and the APEX AMI Trial—Reply. JAMA - Journal of the American Medical Association, 2007, 297, 1877.	7.4	0
579	Anticoagulation for venous thromboembolism. BMJ: British Medical Journal, 2007, 334, 645-645.	2.3	5
580	Who Is (Still) Getting HIT?. Chest, 2007, 131, 1620-1622.	0.8	28
581	Aspirin resistance. Thrombosis Research, 2007, 120, 337-346.	1.7	49
582	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2007, 50, 1742-1751.	2.8	253
583	Guidelines for the management of acute coronary syndromes 2006. Medical Journal of Australia, 2007, 186, 101-102.	1.7	0
584	Simplifying the diagnosis of pulmonary embolism. Medical Journal of Australia, 2007, 187, 325-326.	1.7	0
585	Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. Journal of Thrombosis and Haemostasis, 2007, 5, 255-263.	3.8	73
586	Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. Journal of Thrombosis and Haemostasis, 2007, 5, 1438-1443.	3.8	106
587	VITATOPS, the VITamins TO Prevent Stroke Trial: Rationale and Design of a Randomised Trial of B-Vitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke (NCT00097669) (ISRCTN74743444). International Journal of Stroke, 2007, 2, 144-150.	5.9	38
588	Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk. Clinical Cardiology, 2007, 30, 1124-1134.	1.8	43
589	Role of protein Z in stroke. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 191-197.	0.9	2
590	Nonbleeding complications of unfractionated and low-molecular weight heparins. Clinical Advances in Hematology and Oncology, 2007, 5, 871-3.	0.3	2
591	Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency. Annals of Internal Medicine, 2006, 144, 673.	3.9	365
592	Aspirin resistance. Lancet, The, 2006, 367, 606-617.	13.7	503
593	ESPRIT trial. Lancet, The, 2006, 368, 447.	13.7	0
594	Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes. Circulation, 2006, 114, 774-782.	1.6	1,196

#	ARTICLE	IF	CITATIONS
595	Monitoring unfractionated heparin with the aPTT: Time for a fresh look. <i>Thrombosis and Haemostasis</i> , 2006, 96, 547-552.	3.4	141
596	Homocysteine-Should We Screen and Treat in Preventive Cardiology Programs?. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2006, 26, 281-287.	0.5	0
597	The tissue factor pathway in ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 527-532.	1.0	15
598	More on: enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1639-1640.	3.8	1
599	Bleeding and management of bleeding. <i>Country Review Ukraine</i> , 2006, 8, G38-G45.	0.8	60
600	Methylenetetrahydrofolate Reductase Polymorphisms and Homocysteine-Lowering Effect of Vitamin Therapy in Singaporean Stroke Patients. <i>Stroke</i> , 2006, 37, 456-460.	2.0	36
601	Management of Antiphospholipid Antibody Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1050.	7.4	390
602	Medical Management of Peripheral Arterial Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 41.	7.4	0
603	Treatment of Antiphospholipid Antibody Syndrome—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 42.	7.4	2
604	Association between phosphodiesterase 4D gene and ischaemic stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1067-1069.	1.9	65
605	Medical Treatment of Peripheral Arterial Disease. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 547.	7.4	285
606	Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia. <i>Archives of Internal Medicine</i> , 2006, 166, 729.	3.8	259
607	The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin. <i>Evidence-Based Medicine</i> , 2006, 11, 120-120.	0.6	0
608	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). <i>Vascular Health and Risk Management</i> , 2006, 2, 379-387.	2.3	3
609	Aspirin resistance: does it exist and is it an important clinical problem?. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 268-70.	0.3	0
610	Monitoring unfractionated heparin with the aPTT: time for a fresh look. <i>Thrombosis and Haemostasis</i> , 2006, 96, 547-52.	3.4	57
611	High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1094-1095.	3.8	21
612	Aspirin resistance: position paper of the Working Group on Aspirin Resistance. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1309-1311.	3.8	315

#	ARTICLE	IF	CITATIONS
613	Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2649-2655.	3.8	50
614	Bone marrow biopsy in thrombocytopenic or anticoagulated patients. <i>British Journal of Haematology</i> , 2005, 129, 562-563.	2.5	12
615	Bone marrow biopsy morbidity and mortality: 2002 data.. <i>International Journal of Laboratory Hematology</i> , 2005, 27, 209-210.	0.2	1
616	von Willebrand Disease Associated with Superficial Temporal Artery Pseudoaneurysm. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005, 30, 285-287.	1.5	7
617	Venous thromboembolism: diagnosis and management of deep venous thrombosis. <i>Medical Journal of Australia</i> , 2005, 182, 476-481.	1.7	38
618	Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. <i>Medical Journal of Australia</i> , 2005, 182, 199-199.	1.7	2
619	Venous thromboembolism: diagnosis and management of pulmonary embolism. <i>Medical Journal of Australia</i> , 2005, 183, 220-221.	1.7	0
620	Venous thromboembolism: diagnosis and management of pulmonary embolism. <i>Medical Journal of Australia</i> , 2005, 182, 569-574.	1.7	25
621	Adding aspirin to clopidogrel after TIA and ischemic stroke. <i>Neurology</i> , 2005, 64, 1117-1121.	1.1	21
622	Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction. <i>Circulation</i> , 2005, 112, 3855-3867.	1.6	130
623	Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005, 83, 98-103.	1.4	14
624	Sustained Homocysteine-Lowering Effect over Time of Folic Acid-Based Multivitamin Therapy in Stroke Patients despite Increasing Folate Status in the Population. <i>Cerebrovascular Diseases</i> , 2005, 19, 110-116.	1.7	15
625	Homocysteine-Lowering Treatment With Folic Acid, Cobalamin, and Pyridoxine Does Not Reduce Blood Markers of Inflammation, Endothelial Dysfunction, or Hypercoagulability in Patients With Previous Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2005, 36, 144-146.	2.0	94
626	Protein Z Gene Polymorphisms, Protein Z Concentrations, and Ischemic Stroke. <i>Stroke</i> , 2005, 36, 1123-1127.	2.0	50
627	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2005, 26, 2396-2403.	2.2	24
628	Homocysteine and stroke. <i>Lancet</i> , The, 2005, 365, 194-196.	13.7	24
629	Low Molecular Weight Heparin and Bleeding in Patients with Severe Renal Failure: A Meta-Analysis.. <i>Blood</i> , 2005, 106, 907-907.	1.4	1
630	Clinical usefulness of plasma homocysteine in vascular disease. <i>Medical Journal of Australia</i> , 2004, 181, 314-318.	1.7	46

#	ARTICLE	IF	CITATIONS
631	Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Medical Journal of Australia, 2004, 181, 150-154.	1.7	87
632	Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. Medical Journal of Australia, 2004, 181, 524-525.	1.7	15
633	The beginning of the end of warfarin?. Medical Journal of Australia, 2004, 180, 549-551.	1.7	8
634	Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opinion on Pharmacotherapy, 2004, 5, 493-503.	1.8	18
635	Red cell N5-methyltetrahydrofolate concentrations and C677T methylenetetrahydrofolate reductase genotype in patients with stroke. Journal of Clinical Pathology, 2004, 57, 54-57.	2.0	10
636	Ximelagatran or Warfarin for Stroke Prevention in Patients With Atrial Fibrillation?. Stroke, 2004, 35, 389-391.	2.0	16
637	Folic Acid-Based Multivitamin Therapy to Prevent Stroke. Stroke, 2004, 35, 1995-1998.	2.0	9
638	Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. Journal of Thrombosis and Haemostasis, 2004, 2, 2067-2069.	3.8	35
639	Failure of Aspirin to Prevent Atherothrombosis. American Journal of Cardiovascular Drugs, 2004, 4, 57-67.	2.2	27
640	Adjunctive Use of Direct Thrombin Inhibitors in Patients Receiving Fibrinolytic Therapy for Acute Myocardial Infarction. American Journal of Cardiovascular Drugs, 2004, 4, 107-115.	2.2	5
641	Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism. Circulation, 2004, 110, 744-749.	1.6	578
642	Ximelagatran or warfarin in atrial fibrillation?. Lancet, The, 2004, 363, 734.	13.7	6
643	Renal Function, Peak Anti-Xa Levels and Enoxaparin Dosing. Journal of Pharmacy Practice and Research, 2004, 34, 14-17.	0.8	8
644	Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. Blood Coagulation and Fibrinolysis, 2004, 15, 129-130.	1.0	2
645	Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant. Blood Coagulation and Fibrinolysis, 2004, 15, 353-357.	1.0	4
646	Aspirin resistance: Table 1. BMJ: British Medical Journal, 2004, 328, 477.	2.3	94
647	Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism. Annals of Internal Medicine, 2004, 140, 175.	3.9	333
648	Low-Molecular-Weight Heparin for Pulmonary Embolism. Annals of Internal Medicine, 2004, 141, 407.	3.9	0

#	ARTICLE	IF	CITATIONS
649	High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in antiphospholipid antibody syndrome. ACP Journal Club, 2004, 140, 38.	0.1	0
650	Thromboprophylaxis practice patterns in two Western Australian teaching hospitals. Haematologica, 2004, 89, 586-93.	3.5	20
651	High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in the antiphospholipid antibody syndrome. ACP Journal Club, 2004, 140, 38.	0.1	0
652	Collagen platelet receptor polymorphisms integrin $\alpha_2\beta_1$ C807T and GPVI Q317L and risk of ischemic stroke. Journal of Thrombosis and Haemostasis, 2003, 1, 963-970.	3.8	35
653	SUBOPTIMAL PREVENTIVE PRACTICES IN PATIENTS WITH CAROTID AND PERIPHERAL VASCULAR OCCLUSIVE DISEASE IN A TERTIARY REFERRAL SETTING. ANZ Journal of Surgery, 2003, 73, 932-937.	0.7	11
654	Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia. ANZ Journal of Surgery, 2003, 73, 826-829.	0.7	9
655	Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. Journal of Thrombosis and Haemostasis, 2003, 1, 2689-2691.	3.8	44
656	The evolving role of direct thrombin inhibitors in acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, S70-S78.	2.8	35
657	Aspirin resistance: a new independent predictor of vascular events? **Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. Journal of the American College of Cardiology, 2003, 41, 966-968.	2.8	108
658	C-reactive protein in ischemic stroke and its etiologic subtypes. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 74-81.	1.6	38
659	Does This Patient Have Pulmonary Embolism?. JAMA - Journal of the American Medical Association, 2003, 290, 2849.	7.4	147
660	Editorial Comment "Routine Thrombophilia Testing in Stroke Patients Is Unjustified. Stroke, 2003, 34, 1826-1827.	2.0	15
661	Endothelial and Platelet Activation in Acute Ischemic Stroke and Its Etiological Subtypes. Stroke, 2003, 34, 2132-2137.	2.0	147
662	Protein Z in Ischemic Stroke and its Etiologic Subtypes. Stroke, 2003, 34, 2415-2419.	2.0	73
663	Antiplatelet Agents in Acute Coronary Syndromes. Seminars in Vascular Medicine, 2003, 03, 403-414.	2.1	4
664	Cyclooxygenase-2 Inhibitors. Stroke, 2003, 34, 2736-2740.	2.0	27
665	Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagulation and Fibrinolysis, 2003, 14, 713-717.	1.0	81
666	Venous thromboembolism in travellers. Blood Coagulation and Fibrinolysis, 2003, 14, 671-675.	1.0	21

#	ARTICLE	IF	CITATIONS
667	Antiplatelet drugs. Medical Journal of Australia, 2003, 178, 568-574.	1.7	54
668	In reply: Low molecular weight heparins and heparinoids. Medical Journal of Australia, 2003, 178, 414-415.	1.7	0
669	Long-term management of venous thromboembolism: is there a role for low-intensity warfarin therapy?. Medical Journal of Australia, 2003, 179, 68-69.	1.7	1
670	Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention. ACP Journal Club, 2003, 138, 33.	0.1	0
671	Review: MTHFR TT genotype increases risk for coronary heart disease. ACP Journal Club, 2003, 138, 79.	0.1	0
672	Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention. ACP Journal Club, 2003, 138, 33.	0.1	1
673	Review: MTHFR TT genotype increases risk for coronary heart disease. ACP Journal Club, 2003, 138, 79.	0.1	0
674	Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. Circulation, 2002, 105, 1650-1655.	1.6	1,040
675	Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. European Heart Journal, 2002, 23, 117-123.	2.2	25
676	Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. European Heart Journal, 2002, 23, 1771-1779.	2.2	60
677	Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. New England Journal of Medicine, 2002, 346, 1589-1590.	27.0	8
678	Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement. Archives of Internal Medicine, 2002, 162, 1465.	3.8	170
679	Management of Patients with Acute Coronary Syndromes. Drugs, 2002, 62, 1839-1852.	10.9	6
680	Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet, The, 2002, 359, 294-302.	13.7	251
681	The tip of the iceberg?. Lancet, The, 2002, 359, 2194.	13.7	1
682	Direct thrombin inhibitors in acute coronary syndromes. Lancet, The, 2002, 360, 492.	13.7	2
683	Aspirin for the primary prevention of cardiovascular events. Medical Journal of Australia, 2002, 177, 343-344.	1.7	3
684	Low molecular weight heparins and heparinoids. Medical Journal of Australia, 2002, 177, 379-383.	1.7	42

#	ARTICLE	IF	CITATIONS
685	Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2002, 69, 315-317.	2.2	12
686	Design of trials to evaluate antiplatelet agents. , 2002, , 1003-1012.		0
687	Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction11 Drs. Mehta and Eikelboom were recipients of Heart and Stroke Foundation of Canada Research Fellowship Awards. Professor Yusuf is the recipient of a Medical Research Council of Canada Senior Scientist Award and holds a Heart and Stroke Foundation of Ontario Research Chair.. <i>Journal of the American College of Cardiology</i> , 2001, 37, 37-43.	2.8	364
688	Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. <i>Lancet, The</i> , 2001, 358, 9-15.	13.7	489
689	Homocysteine Levels in Patients with Stroke. <i>CNS Drugs</i> , 2001, 15, 437-443.	5.9	19
690	Routine home treatment of deep vein thrombosis. <i>BMJ: British Medical Journal</i> , 2001, 322, 1192-1193.	2.3	19
691	Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 377-383.	2.0	18
692	Platelet glycoprotein Ib± Kozak polymorphism is associated with an increased risk of ischemic stroke. <i>Blood</i> , 2001, 98, 36-40.	1.4	94
693	Inherited Thrombophilia in Ischemic Stroke and Its Pathogenic Subtypes. <i>Stroke</i> , 2001, 32, 1793-1799.	2.0	133
694	Homocysteine and stroke. <i>Current Opinion in Neurology</i> , 2001, 14, 95-102.	3.6	106
695	Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 444.	7.4	29
696	Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation. <i>Circulation</i> , 2001, 103, 643-650.	1.6	43
697	Detection of protein s deficiency: a new functional assay compared to an antigenic technique. <i>Pathology</i> , 2000, 32, 94-97.	0.6	5
698	The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. <i>European Heart Journal</i> , 2000, 21, 2033-2041.	2.2	248
699	Association Between High Homocyst(e)ine and Ischemic Stroke due to Large- and Small-Artery Disease but Not Other Etiologic Subtypes of Ischemic Stroke. <i>Stroke</i> , 2000, 31, 1069-1075.	2.0	229
700	Management of unstable angina and myocardial infarction. <i>Lancet, The</i> , 2000, 356, 1193-1194.	13.7	1
701	Intracranial haemorrhage with bolus thrombolytic agents. <i>Lancet, The</i> , 2000, 356, 1850.	13.7	4
702	Enoxaparin was superior to heparin in preventing serious cardiac ischemic events in patients with unstable angina/non-Q-wave MI. <i>Evidence-based Cardiovascular Medicine</i> , 2000, 4, 45.	0.0	0

#	ARTICLE	IF	CITATIONS
703	Management of unstable coronary-artery disease. Lancet, The, 2000, 355, 572.	13.7	1
704	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet, The, 2000, 355, 1936-1942.	13.7	419
705	Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet, The, 2000, 356, 449-454.	13.7	74
706	Homocyst(e)ine and Cardiovascular Disease. Annals of Internal Medicine, 2000, 132, 676.	3.9	10
707	Prothrombin 20210A and familial thrombophilia. Blood Coagulation and Fibrinolysis, 1999, 10, 523-527.	1.0	0
708	Preventing Thromboembolic Complications in Older Orthopaedic Surgery Patients. Drugs and Aging, 1999, 15, 297-306.	2.7	2
709	Homocysteine and vascular disease. Lancet, The, 1999, 354, 407-413.	13.7	914
710	Homocysteine and cardiovascular risk: is it time to treat?. Evidence-based Cardiovascular Medicine, 1999, 3, 59-60.	0.0	0
711	Broadsheet number 53: activated protein c resistance: diagnosis and clinical management. Pathology, 1999, 31, 365-371.	0.6	0
712	Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence. Annals of Internal Medicine, 1999, 131, 363.	3.9	781
713	Low-molecular-weight Heparin for the treatment of venous thrombosis in patients with adenocarcinoma. , 1998, 59, 260-261.		14
714	Venous thrombosis and hyperhomocysteinaemia. Medical Journal of Australia, 1998, 169, 313-315.	1.7	4
715	Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all-trans retinoic acid therapy for acute promyelocytic leukemia. , 1997, 15, 13-17.		3
716	Cyclooxygenase Inhibitors. , 0, , 31-46.		0
717	Thrombolytic Therapy for Deep Vein Thrombosis and Pulmonary Embolism. , 0, , 88-98.		0